A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217649/
Allen Yan Lun Liu, Serena Low, Ester Yeoh, Eng Kuang Lim, Claude Jeffrey Renaud, Selene Tse Yen Teoh, Grace Feng Ling Tan, Chung Cheen Chai, Bo Liu, Tavintharan Subramaniam, Chee...
Conclusions: This real-world study demonstrates the benefits of SGLT2is on CKD progression and ESKD. The effect is more pronounced in moderate to advanced CKD patients.
Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
Source : https://www.sciencedirect.com/science/article/pii/S2001037022002136?via=ihub
Repositioning or repurposing drugs account for a substantial part of entering approval pipeline drugs, which indicates that drug repositioning has huge market potential and value. Computational technologies such as machine...
Conclusion/Relevance: In this review, we focus on the machine learning methods for the development of new T2DM drugs and give an overview of the repurposing potential of the existing antidiabetic agents.
Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis
Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402122001539?via=ihub
Weekly low dose semaglutide is effective in reducing alanine aminotransferase (ALT). * This beneficial impact of injectable semaglutide is seen in people with or without type-2 diabetes. * Numbers of...
Conclusion: This meta-analysis provides reassuring data on efficacy of low dose semaglutide injections in improving ALT and certain radiologic features in MAFLD. Current conclusions are limited by small number of patients evaluated. Urgent need remains for larger studies focussing on liver biopsy.
-
Dr Hamid4yrSemaglutide mg weekly is effective in improving ALT and other components of metabolic syndrome
-
Type 2 Diabetes Connect4yrKey Points • Source: Cardiovascular Diabetology • Conclusions: “This meta-analysis provides reassuring data on efficacy of low dose semaglutide injections in improving ALT and certain radiologic features in MAFLD [metabolic-dysfunction associated fatty-liver disease]. Current Show More
An overview of current therapy options of non-alcoholic fatty liver disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35728962/
Finding an effective treatment of non-alcoholic fatty liver disease (NAFLD) remains one of main challenges in hepatological research for the 21st century, since there is no such a treatment yet....
Conclusion/Relevance: Current pharmacological treatment of NAFLD comprises screening and therapy of metabolic syndrome components and minimizing of alcohol intake. There are new substances being evaluated in clinical trials, the most promising ones are semaglutide and lanifibranor.
-
Dr Hamid4yr(NAFLD) remains one of main challenges In patients with DM II and obesity
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35737858/
BACKGROUND: The rising prevalence and associated public health burden of obesity has led to advancements in pharmaceuticals for weight management. Semaglutide 2.4 mg, an anti-obesity medication (AOM) recently approved by...
CONCLUSIONS: As a long-term weight management therapy, semaglutide 2.4 mg was estimated to be cost-effective compared with no treatment, D&E alone, and all other branded AOM comparators under a WTP threshold of $150,000 per QALY gained over a 30-year time horizon.
-
Dr Hamid4yrsemaglutide 2.4 mg was estimated to be cost-effective option for patients